Medical devices and healthcare corporation Abbott Laboratories (NYSE:ABT) recently announced that its new cardiac mapping platform, the EnSite™ X EP System with EnSite Omnipolar Technology (OT), has received clearance from the U.S. Food and Drug Administration (FDA). The mapping platform is aimed at assisting doctors to better treat abnormal heart rhythms. Following the news, shares of the company declined 1.5% on Wednesday. The stock pared its loss slightly to close at $133.76 in the extended trading session.
https://www.tipranks.com/news/abbotts-cardiac-mapping-system-receives-fda-approval?utm_source=advfn.com&utm_medium=referral
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Abbott Laboratories Charts.